Proteins bud from cells in small single-membraned vesicles (∼50-250 nm) that have the same topology as the cell. Known variously as exosomes and microvesicles (EMVs), these extracellular organelles are enriched for specific proteins, lipids, carbohydrates and nucleic acids. EMV biogenesis plays critical roles in protein quality control and cell polarity, and, once released, EMVs can transmit signals and molecules to neighbouring cells via a non-viral pathway of intercellular vesicle traffic. In the present paper, we discuss the cis-acting targeting signals that target proteins to EMVs and mediate protein budding from the cell.
(∼0.5-2 μm or more) by differential centrifugation: larger vesicles sediment at ∼10 000 g (after 30-60 min), whereas the smaller class of secreted vesicles pellet preferentially at higher force, ∼100 000 g (after 60-90 min) [16, 17] . In fact, it has been proposed that these two classes of vesicles be named differently, with the term 'microvesicle' used to describe the larger vesicles that pellet at ∼10 000 g, and 'exosome' used to describe the smaller class of secreted vesicles that pellet at ∼100 000 g [18] . Other investigators have proposed a pair of biogenic definitions, with vesicles that bud from the plasma membranes being called 'microvesicles', and 'exosome' referring only to extracellular vesicles that arise by (i) budding into endosomes, and (ii) fusion of vesicle-containing endosomes with the plasma membrane [3] . However, there are two substantial flaws with this latter approach: first, there is as yet no evidence for a significant mechanistic difference between vesicle budding at the plasma and endosome membranes; and, secondly, the definition is empirically unworkable because it is not possible to separate vesicles of similar physical and molecular properties based on the membrane from which they arose. In this context, it is difficult to know exactly which terms should be applied to which vesicles. In lieu of a better option, our group refers to the smaller class of secreted vesicle by the hybrid term exosome/microvesicle, or EMV [19] [20] [21] [22] , even though it conforms to the empirical (i.e. centrifugal sedimentationbased [18] ) definition of an exosome.
EMV biogenesis: cis-acting EMV targeting signals
EMV biogenesis involves (i) the trafficking of cargo molecules to sites of outward vesicle budding (outward = away from the cytoplasm), (ii) enrichment of cargo molecules in nascent vesicles, (iii) scission of cargo-containing vesicles from the cell membrane, and (iv) the release of vesicles into the extracellular milieu. As with all organelle biogenesis pathways, the cisacting signals that target proteins to EMVs are likely to provide important insights into the mechanisms of EMV biogenesis and protein budding. One of the earliest studies on the cis-acting signals sufficient to target proteins to EMVs was by Fang et al. [23] , which demonstrated that plasma membrane binding and higher-order oligomerization are sufficient to target proteins to sites of vesicle budding and into EMVs. This conclusion was based on two separate, but complementary, observations: first, that antibody-induced higher-order oligomerization of cell-surface proteins led to their secretion from the cell in EMVs; and, secondly, that addition of a plasma membrane anchor was sufficient to target a highly oligomeric cytoplasmic protein to EMVs [23] . Shen et al. [22] extended these observations by showing that (i) plasma membrane anchors can target additional unrelated cytoplasmic proteins into EMVs, (ii) EMV targeting can be induced by a wide array of plasma membrane anchors [a myristoylation tag, a prenylation/palmitoylation tag, a PtdIns(4,5)P 2 -binding domain, a PtdIns(3,4,5)P 3 -binding domain and a type-1 integral plasma membrane protein], and (iii) these plasma membrane anchors can be placed at either the N-terminal or the C-terminal end of the cargo proteins and still target them to EMVs [22] .
Shen et al. [22] also reported the somewhat surprising finding that endosome membrane anchors are unable to target proteins into EMVs, even though the exact same test proteins were readily targeted to EMVs by plasma membrane anchors. These findings run counter to the widespread presumption that the endosome is a major site of vesicle biogenesis. However, they are highly similar to what has been found for retrovirus budding, a process that is driven by Gag, the major structural protein of retroviruses. Specifically, it has been demonstrated that (i) retroviral Gag proteins possess plasma membrane anchors, not endosome membrane anchors [24] , (ii) rational targeting of Gag to the plasma membrane with heterologous plasma membrane anchors continues to support its budding and infectivity [25] , and (iii) rational targeting of Gag to endosome membranes cannot support virus budding from the cell [25] .
Do EMV cargoes have the predicted properties?
The hypothesis that plasma-membrane-binding and higherorder oligomerization target proteins to EMVs makes a number of predictions about the nature of EMV cargo proteins. The most direct prediction is that known EMV cargoes form higher-order oligomeric complexes in or on the plasma membrane. This appears to be the case. Tetraspanins represent some of the most widely used exosome marker proteins (e.g. CD9, CD63, CD81 and CD82 [26] ), are all plasma membrane proteins, and are commonly found in large heterogeneous complexes (e.g. the 'tetraspanin web' [27] ). Another example are the ERM (ezrin/radixin/ moesin) proteins and other adaptors [e.g. EBP50 (ERMbinding protein 50)] that cross-link actin filaments to selected plasma membrane proteins, generating large heterooligomeric complexes [28] that enter the EMV protein sorting pathway [29] [30] [31] . The Gag proteins of endogenous and exogenous retroviruses represent yet another group of EMV cargo proteins that possess a plasma membrane anchor and multiple oligomerization domains [32, 33] . Furthermore, detailed studies of the HIV Gag protein have demonstrated that these properties, i.e. higher-order oligomerization and plasma membrane binding, are its primary budding information [23] . In fact, the mechanistic similarity between retrovirus budding and EMV biogenesis is so strong that one can target virtually any plasma membrane protein to the surface of HIV particles merely by inducing its higher-order oligomerization [23] .
The hypothesis that proteins are targeted to EMVs on the basis of higher-order oligomerization and plasma membrane binding also predicts that a protein's trafficking to EMVs can be regulated, by altering its affinity for the plasma membrane and/or degree of oligomerization. Several lines of evidence satisfy this prediction, including the differential trafficking of TfR (transferrin receptor) to EMVs during reticulocyte maturation [34] [35] [36] , the antibody-induced budding of antigen receptors from B-cells and T-cells [14, 23] , the aggregationinduced budding of the prion protein [37, 38] , and the rapid and reversible trafficking of uropod proteins to sites of EMV budding during the polarization of human leucocytes [21] .
A third prediction of our operating hypothesis is that EMV cargo proteins will, in general, lack shared amino acid sequence motifs or features. This prediction is based on the fact that a wide array of sequences can confer plasma membrane binding and/or higher-order oligomerization. For example, plasma membrane binding can be mediated by a diverse array of sequence motifs and structures, from acylation sites (e.g. a glycine residue at position 2 of a protein, which can confer its N-myristoylation) to phospholipidbinding domains such as those that bind PtdIns(4,5)P 2 or PtdIns(3,4,5)P 3 [22] . As for protein oligomerization, it too is mediated by unrelated sequences that range from the simple (e.g. a leucine zipper), moderately complex (e.g. oligomerization interfaces on large globular enzymes) to highly complex [e.g. the multiple protein and RNA contacts in large RNP (ribonucleoprotein) complexes] amino acid sequences. This prediction matches empirical observations, as EMVs contain proteins as diverse as tetraspanins, integrins, MHC proteins, chaperones, RNPs, cytoskeletal proteins and retroviral Gag proteins.
ESCRTs and ESCRT-binding sites in protein budding
Perhaps the most intriguing group of EMV cargoes are the ESCRTs (endosomal sorting complexes required for transport) [39] [40] [41] . These protein complexes (ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III) are best known for their roles in the trafficking of ubiquitylated plasma membrane proteins to lysosomes in a pathway that involves their (i) endocytosis, (ii) trafficking to the limiting membrane of endosomes, (iii) budding into the endosome lumen, (iv) delivery to the lysosome lumen, and (v) lysosomal destruction. However, ESCRT proteins are also found at high levels at the plasma membrane [42] and are characterized by their presence in membrane-bound highly oligomeric protein complexes. Given that these properties are sufficient to target proteins to EMVs, it is not surprising that many ESCRT proteins are enriched in secreted vesicles [43] [44] [45] . The targeting of ESCRT proteins to EMVs can also be seen in the constitutive budding of oligomeric membrane-associated ESCRT-III proteins that lack their autoinhibitory C-terminal domain [46] . Not surprisingly, a protein's association with ESCRT components can, in some instances, trigger its budding from the cell. For example, the budding of ARRDC1 (arrestin domain-containing protein-1) [47] , and of syntenin [48] , appears to be mediated by their Tsg101 (tumour susceptibility gene 101)-binding motif [P(T/S)AP] and Alix [ALG-2 (apoptosis-linked gene 2)-interacting protein X]-binding motif (YPXL) respectively. One way to interpret these findings is that the binding of ARRDC1 and/or syntenin with their ESCRT ligands converts them into plasma-membrane-localized higher-order oligomeric complexes that enter the EMV protein sorting pathway.
Another way to interpret these observations is that the ESCRT-binding motifs induce the budding of proteins such as ARRDC1 and syntenin by recruiting a catalytic activity of the ESCRT machinery. In vivo, loss of ESCRT function can inhibit several topologically similar processes, including the biogenesis of most (but not all) MVBs (multivesicular bodies), cytokinesis and the budding of several enveloped viruses, particularly HIV and other retroviruses [40, 41, 49, 50] . Furthermore, in vitro studies have established that the addition of constitutively oligomeric ESCRT-III proteins to phospholipid membranes results in their budding into small vesicles [51] . These and other observations have led to the hypothesis that a major role of ESCRTs is to catalyse the scission of nascent vesicles from parent membranes. However, other lines of evidence raise doubts about whether this mechanistic model applies to the role of ESCRTs in EMV biogenesis. First, protein ubiquitylation, the primary signal for engagement with the ESCRT machinery, does not target membrane proteins to EMVs [23] . Secondly, inhibition of ESCRT function fails to impair EMV biogenesis [23] , a result that has been replicated subsequently [52] . Thirdly, the fact that ESCRT-III proteins causes budding of vesicles from synthetic membranes in vitro demonstrates that vesicle budding is not only a cargo-dependent process, but is also a cargo-driven process. The emerging complexity of the role that ESCRTs play in EMV biogenesis is underscored by the observation that VPS4 (vacuolar protein sorting 4), an AAA (ATPase associated with various cellular activities) protein that dissociates ESCRT-III protein complexes, also binds to other EMV cargo proteins such as CD63 and CD81 [19] , even though these proteins bud from cells in an ESCRTindependent manner [23] .
Other cargoes, other signals
Although higher-order oligomerization and plasma membrane binding might be the primary signals for targeting proteins into nascent vesicles, it is unlikely that all EMV cargoes will possess these properties. For instance, virtually any cytoplasmic protein could be brought into nascent EMVs, piggyback style, merely by binding to an EMV cargo protein. In addition to potentially explaining the import of some ESCRT-associated proteins such as Alix or ARRDC1, a piggyback mechanism might also explain the vesicular secretion of αB-crystallin [53, 54] and chaperones [55, 56] , proteins that are known to bind misfolded and aggregated plasma membrane proteins. As for the existence of completely distinct mechanisms for targeting proteins to secreted vesicles, precedent alone suggests that these are likely to exist, as multiple signals are able to target proteins to all other organelles. In fact, the vesicular budding of MFG-E8 (milk fat globule-epidermal growth factor factor 8 protein)/lactadherin appears to involve a distinct mechanism: MFG-E8/lactadherin is co-translationally translocated into the endoplasmic reticulum lumen, secreted by the classic exocytic pathway, and is recruited to the outer surface of EMVs via its phosphatidylserine-binding C2 domains [57, 58] .
EMVs are also enriched for specific nucleic acids, particularly miRNAs (microRNAs) [59, 60] . Given that RNAs typically exist in complex with proteins, their selective enrichment in EMVs is likely to be another case of piggyback trafficking, wherein the selective trafficking of one or more RNA-binding proteins to EMVs results in the selective budding of their cognate RNAs. Numerous RNPs have been reported in EMVs, including RNPA2B1 (heterogeneous RNP A2/B1) [61] and RBM3 (RNA-binding motif protein 3) [62] . However, the most abundant RNA-binding proteins in EMVs are retroviral Gag proteins expressed from endogenous retroviruses [63] . Gag proteins bind a wide array of RNA species, are capable of incorporating long RNAs of up to 10 kb in length into a secreted vesicle, and might represent the mechanistic basis for EMV-mediated intercellular traffic of mRNAs. The vesicular secretion of miRNAs might also be mediated by Gag proteins or other RNA-binding proteins that are secreted from the cell in EMVs, such as RNPA2B1 [61] or the RISC (RNA-induced silencing complex) components GW182 and Argonaut [64] .
Covalent linkage to EMV cargo proteins is another potential mode of EMV protein targeting. For example, the isopeptide linkage of ubiquitin to highly oligomeric plasma membrane proteins is likely to explain its presence in secreted vesicles [65] . Another example is the enrichment of specific carbohydrate adducts on surface glycoproteins and glycolipids, particularly high mannose, polylactosamine and α-2,6-sialic acid residues [66] . The discovery of shared carbohydrate residues on the surface of EMVs is intriguing, for it suggests that either (i) this carbohydrate modification is selectively added to EMVs cargos, or (ii) addition of this carbohydrate moiety somehow targets glycoproteins and glycolipids to sites of EMV budding. Either way, it suggests that a better understanding of EMVselective carbohydrate modifications will lead to a better understanding of EMV biogenesis. Interestingly, the same carbohydrates that are enriched on the surface of EMVs are also enriched on the surface of HIV particles [67] .
The biogenesis of EMVs also involves the selective targeting of specific lipids to sites of vesicle budding and their enrichment in nascent vesicles. EMVs are typically enriched for cholesterol and sphingolipids, and ceramide has even been implicated as a catalyst of vesicle budding [52, 68] . The selective trafficking of lipids to EMV budding has also been observed for N-modified forms of PE (phosphatidylethanolamine), including 1,2-dioleoyl-sn-glycero-3-PE-N-(lissamine rhodamine B sulfonyl), 1,2-dioleoyl-snglycero-3-PE-N-(carboxyfluorescein) and 1,2-dioleoylsn-glycero-3-PE-N-(biotinyl) [33, 69] . Specifically, when these lipids are incorporated into the outer leaflet of the plasma membrane of living cells, they are rapidly trafficked to sites of EMV biogenesis and secreted from the cell in vesicles. Interestingly, depletion of cholesterol by addition of methyl-β-cyclodextrin to the culture medium causes the release of these N-modified forms of PE from sites of vesicle budding and their redistribution to the plasma membrane in general, as well as to endomembrane structures [33] . However, cholesterol depletion does not alter the enrichment of EMV cargo proteins at sites of vesicle budding, and removal of methyl-β-cyclodextrin from the medium leads to the re-accumulation of N-modified forms of PE at sites of vesicle budding [33] . The most parsimonious explanation for these varied results is that the sites of vesicle budding are determined by the trafficking of EMV cargo proteins, the enrichment of these cargoes generates a unique membrane domain that attracts specific lipid molecules, and that altering the levels of these lipids can enhance or inhibit the formation of secreted vesicles. It is currently unclear whether these phenomena are determined solely by the intrinsic biophysical properties of EMV lipids and cargo proteins [70] , or whether active sorting mechanisms are involved.
It should also be noted that EMVs contain numerous molecules that are not selectively enriched in EMVs. These EMV components arrive at sites of budding merely by diffusion within the cytoplasm and/or plasma membrane. As such, the mere detection of a protein or lipid in EMVs does not mean that it will possess a specific sorting signal. It also suggests that the bulk proteomic and lipidomic studies of purified EMVs are likely to overestimate the number of EMV-targeted proteins, since additional tests are required to determine whether a given cargo is actually enriched in secreted vesicles, or whether it is present in EMVs due to diffusion alone.
Future directions
The identification of cis-acting signals that target proteins to EMVs represents the first step in understanding EMV biogenesis. Next, it will be important to understand how the cell recognizes proteins that contain these signals, trafficks them to sites of EMV budding, and secretes them from the cell in vesicles. In the case of the ESCRT-binding sequence motifs that appear to promote the budding of at least some EMV cargoes, much can be deduced from the existing knowledge about these well-studied motifs and the ESCRT machinery, which should lead to relatively rapid progress on this front. A greater challenge lies in elucidating how higher-order oligomerization and plasma membrane binding generate a discrete biochemical signal, how this signal might be recognized by the cell, and how signal-containing proteins and/or protein complexes are targeted to EMVs.
